J. Goldman & Co’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

J. Goldman & Co’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,136	Closed	-$438K	–	533
2023 Q2	$438K	Sell	11,136 -165,407	-94%	-$5.84M	0.02%	300
2023 Q1	$4.3M	Sell	176,543 -128,835	-42%	-$2.82M	0.17%	157
2022 Q4	$6.54M	Buy	305,378 +270,971	+788%	+$5.78M	0.32%	91
2022 Q3	$617K	Sell	34,407 -180,808	-84%	-$2.37M	0.03%	283
2022 Q2	$2.07M	Sell	215,215 -130,492	-38%	-$1.64M	0.1%	200
2022 Q1	$5.82M	Buy	345,707 +176,794	+105%	+$2.61M	0.27%	109
2021 Q4	$2.82M	Buy	168,913 +133,650	+379%	+$2.19M	0.16%	166
2021 Q3	$573K	Buy	+35,263	New	+$384K	0.03%	268

J. Goldman & Co's ISEE Position: Q3 2023 in Review

J. Goldman & Co sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 11,136 shares — an estimated $438K sold.

J. Goldman & Co first reported a position in ISEE in Q3 2021 and held it in 8 quarters. The position peaked at $6.54M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

J. Goldman & Co reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
J. Goldman & Co sold 11,136 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $438K.
J. Goldman & Co first reported a position in IVERIC bio, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
J. Goldman & Co's IVERIC bio, Inc. Common Stock position peaked at $6.54M in Q4 2022.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on J. Goldman & Co's 13F filing for Q3 2023, filed 14 Nov 2023.